Login | Register

Novartis Loses In Patent Court Ruling, India

India's Supreme Court turned down Novartis' patent bid for an updated version of Glivec (imatinib mesylate), its blockbusting leukemia medication, saying that the updated compound "did not satisfy the test of novelty or inventiveness" required by the country's legislation. The ruling means that generic drugmakers can continue manufacturing and selling copies of Glivec at low prices...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *